Overview

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

Status:
Not yet recruiting

Trial end date:
2027-01-29

Target enrollment:

Participant gender:

Summary

A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Durvalumab
Lenvatinib
Tremelimumab